Alzheon Patents

Patent portfolio assigned to Alzheon (verified via public assignee records). Estimated patent count: 5. Clinical-stage Alzheimer's biopharma (oral ALZ-801/valiltramiprosate). Competitors are the approved anti-amyloid antibodies it positions against (Leqembi, Kisunla, Aduhelm). Patents confirmed assigned to Alzheon Inc on Google Patents (e.g. WO2017044840A1) and Justia; several US patents granted 2024-2025 (12285400, 12187668, 12083082, 12036208). As a drug-development company it has no commercial customers. Patent count is a visible lower-bound estimate.